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Summ a r y
The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often 
used to treat chronic infection with hepatitis B virus (HBV) until resistance devel-
ops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir 
(Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe 
three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, 
Gilead). All three cases involved a rare HBV variant with a valine at position 233 of 
the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type 
virus. This HBV variant also displayed resistance to adefovir and sensitivity to teno-
fovir in vitro.
A defovir, an inhibitor of hbv reverse transcriptase, can be used as a licensed drug for the treatment of chronic HBV infection.1-3 Virtually 100 percent efficacy has been suggested in lamivudine-resistant HBV infec-
tions,4 but in two reports5,6 only 39 of 46 patients and 13 of 18 patients, respec-
tively, had a marked treatment response. Resistance to lamivudine developed in all 
three of our patients with chronic hepatitis B, and all three had a response to teno-
fovir but not to adefovir. HBV isolated from all three patients before adefovir ther-
apy had the same rtI233V mutation in the reverse-transcriptase domain.
c a se r eport s
Patient 1
Patient 1, a 52-year-old man, had had chronic hepatitis B for more than five years. 
He had undergone unsuccessful therapy with pegylated interferon. Subsequent treat-
ment with lamivudine (100 mg per day) had initially suppressed the viremia, result-
ing in fewer than 200 molecules of HBV DNA per milliliter. However, within three 
months, the level of viremia increased again, to 2.5×107 molecules of HBV DNA per 
milliliter (Fig. 1), and a mutation conferring resistance to lamivudine9 — namely, 
the substitution of isoleucine for methionine at position 204 in the reverse-tran-
scriptase domain (rtM204I) — was detected by direct sequencing of the polymerase-
chain-reaction (PCR) product in the first available sample from September 9, 2002. 
After an interval without therapy, during which this mutation reverted to wild-type, 
the reverse-transcriptase inhibitor tenofovir was administered for nine months (300 
mg per day) as an experimental drug for HBV. Tenofovir is licensed for treatment of 
the human immunodeficiency virus (HIV) and has been used successfully to reduce 
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levels of both HIV and HBV in patients infected 
with both viruses.7,10,11 Within the first three 
months, the level of viremia decreased from 
5.5×107 molecules of HBV DNA to 740 molecules 
of HBV DNA per milliliter and remained at simi-
lar levels for another six months. Thereafter, te-
nofovir was replaced by adefovir (10 mg per day) 
because this drug had become licensed for ther-
apy of chronic HBV. However, during the therapy 
with adefovir, the level of viremia increased im-
mediately and within seven months had reached 
1.5×106 molecules of HBV DNA per milliliter. Re-
placement of adefovir with tenofovir again re-
sulted in a substantial decrease in the level of 
viremia. The decrease was not as rapid as it had 
been before, but after 100 weeks of the second 
course of tenofovir therapy, the level of viremia 
was down to the detection limit of the PCR assay 
— at about 30 molecules of HBV DNA per milli-
liter. Throughout the observation period, the pa-
tient had normal or slightly elevated levels of 
alanine aminotransferase. He was positive for an-
tibody against hepatitis Be antigen (HBeAg); se-
quencing showed that the virus had the normal 
precore sequence as well as the core promoter 
mutations T1753C, A1762T, and G1764A known 
to be associated with HBeAg negativity.12
Patients 2 and 3
Patients 2 and 3 were a married couple. Patient 2, 
a 56-year-old man, had received a liver transplant 
in 1993 because of alcoholic liver disease and 
turned out to be infected with HBV during follow-
up. He had had continuous therapy with immuno-
suppressive agents since his liver transplantation. 
Patient 3, his wife, 52 years of age, was found to 
have chronic hepatitis B in 1994. The genomic 
sequences of their viruses were very similar, but 
in Patient 2, the predominant viral variant had a 
normal precore sequence and the stop codon mu-
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Figure 1. Levels of Viremia in Three Patients Receiving 
Lamivudine (LMV), Adefovir (ADF), and Tenofovir (TNF).
The levels of viremia were measured by real-time PCR 
assay as described by Schildgen et al.7 and Jursch et 
al.8 The limit of detection of each assay is 30 mole-
cules of HBV DNA per milliliter. Dashed lines indicate 
transition from one method to another. Values shown 
at zero were negative in the assay for HBV DNA (<30 
molecules per milliliter).
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tation (G1896A), whereas Patient 3 had only wild-
type virus. Both patients were HBeAg-positive. 
Both husband and wife received lamivudine, 
which initially reduced their levels of viremia 
from 107 molecules of HBV DNA per milliliter to 
less than 105 molecules of HBV DNA per millili-
ter. Resistance subsequently developed, and the 
level of viremia increased again (Fig. 1). This in-
crease was presumably caused by the rtM204I mu-
tation associated with resistance to lamivudine, 
which had been identified in the viral population 
of both patients. Patient 3, in addition, had a vi-
rus variant containing the mutation rtV173L (Fig. 
2). Lamivudine therapy was replaced by adefovir 
therapy, but the level of viremia did not change 
significantly in either patient. The substitution 
of tenofovir therapy for adefovir therapy precipi-
tated a rapid decrease in HBV DNA levels, from 
greater than 5×108 molecules of HBV DNA per 
milliliter in Patient 2 and from 4.5×107 molecules 
of HBV DNA per milliliter in Patient 3 to fewer 
than 100 molecules per milliliter in both patients 
at the end of the study (November 24, 2005).
All three patients were infected by a virus with 
the rtI233V mutation. The functional significance 
of this mutation was initially unknown, but the 
nearby mutation rtN236T had been observed in 
cases in which resistance to adefovir had devel-
oped during therapy.13,14
methods and Results
All three patients provided written informed con-
sent for testing. To determine whether the rtI233V 
mutation alone is necessary and sufficient to ren-
der HBV resistant to adefovir, we employed site-
directed mutagenesis to replace the isoleucine at 
position 233 with valine in the wild-type HBV 
genotype D15 using the plasmid vector pTHBV1.3 
and the primer pair 5'CTTTTGTCTTTGGGTg-
TACATTTAAACCCTAAC3' (sense) and 5'GTTA 
GGGTTTAAATGTAcACCCAAAGACAAAAG3' an-
tisense; the lowercase letter indicates the mutated 
nucleotide. The successful introduction of the mu-
tation was confirmed by sequencing. The HepG2 
subclonal cell line C3A (American Type Culture 
Collection) was plated in six-well cell culture 
plates at a confluence of 50 percent (approximate-
ly 1.5×106 cells) and then transfected with 12 μg 
of wild-type or mutated plasmid. On the next day, 
the cells were passaged into 12-well cell-culture 
plates. To eliminate input DNA, cells were incu-
bated with 100 μg per milliliter of DNaseI (Roche) 
at 37°C for two hours. Two days after transfection, 
cells were treated with the free, unmodified drugs 
adefovir, tenofovir (Moravek), or lamivudine at con-
centrations ranging from 0.1 to 3 μM. The medi-
um used to supplement the drugs was renewed 
daily. Cell-culture supernatants and cells were har-
vested on day 6. Replicative intermediates of HBV 
DNA were extracted as described previously,16 
subjected to Southern blotting,17 and hybridized 
with a phosphorus 32–labeled probe generated 
with the Rediprime random prime labeling sys-
tem (Amersham) from full-length HBV DNA. The 
quantity of HBV DNA was significantly decreased 
in treated cells at each concentration of adefovir 
(Fig. 3A). With the wild-type plasmid, a concen-
tration of adefovir of approximately 0.5 μM re-
sulted in 50 percent inhibition, a value slightly 
higher than that described by Yang et al.18 but 
lower than that found by Brunelle et al.19 The 
rtI233V variant required concentrations of adefo-
vir that were about six times as high for a similar 
level of inhibition (Fig. 3A). This factor exceeds 
that of previously described variations between 
naturally occurring strains.18 In contrast, the in-
hibition efficacy of tenofovir or lamivudine did 
not differ significantly between the wild-type and 
the variant HBV DNA. Lamivudine was by far the 
most efficacious drug in this in vitro system. The 
inhibitory effect of all three drugs was most clear-
ly demonstrated by the amount of open circular 
HBV DNA (Fig. 3A); this is the only form leading 
to secreted infectious virus particles.
In order to study the effect of adefovir on the 
production of secreted virus particles, the cell-
culture medium was first treated with DNaseI 
and then digested with proteinase K, and finally, 
the extracted HBV DNA was subjected to PCR.
The amount of released wild-type HBV DNA was 
decreased by about 80 percent, in response to 1.0 
μM of adefovir, whereas the amount of the vari-
ant released decreased only by about 15 percent 
(Fig. 3B). In this assay, the variant required con-
centrations of adefovir that were about 10 times 
as high as those for the wild-type virus for the 
same degree of inhibition. These in vitro data 
confirm that the rtI233V mutation caused the 
adefovir resistance in vivo.
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Discussion
In a large clinical study of the efficacy of adefovir 
as a treatment for chronic hepatitis B, the rtI233V 
mutation was not observed, but the rtN236T or 
rtA181V mutation developed in 5.9 percent of the 
patients within three years. The in vitro efficacy14 
against these adefovir-induced mutants decreased 
by a factor of 2.5 to 13.8. Thus, the decrease of in 
vitro efficacy by a factor of 6 to 10 caused by the 
naturally occurring variant at position rt233 may 
indicate that this variation in vivo is even more 
relevant than previously identified adefovir-induced 
resistance mutations.
The rtI233V mutation was already present be-
fore adefovir therapy was initiated. It was inde-
pendent of lamivudine resistance; as was seen in 
Patient 1, no lamivudine resistance mutation was 
detected at the beginning of adefovir therapy. 
Neither HBeAg status nor the immune status 
seems to be important for adefovir resistance of 
this variant, since these two factors differed in 
the three patients. Furthermore, the variant rtI233V 
was stable during an observation period of up to 
220 weeks in these patients, even without selec-
tive pressure from adefovir therapy.
We identified these three rtI233V strains among 
the strains isolated from 80 patients whose HBV 
had been sequenced in past years at the Institute 
of Medical Virology in Giessen, Germany. Using 
the S gene sequence for genotyping, we identi-
fied 41 patients with genotype D (which has a 
worldwide distribution), 30 with A2, 2 with A1, 
5 with C, 1 with E, and 1 with G plus A2. Our 
three patients had genotype D (subgroup D3)20 
and had closely related but not identical reverse-
transcriptase and S gene sequences. Remarkably, 
all three had the HBsAg subtype corresponding 
to an isoleucine at the polymorphic site 127 of 
the HBsAg protein, which is very rare (3 of 152 
strains) among patients with the genotype D 
worldwide.20 The frequency of the 3 HBV strains 
with the ayw4 subtype and the rtI233V mutation 
among the 80 sequenced HBV strains may not 
reflect the real frequency of such variants in 
Germany. A GenBank search revealed that only 
3 of about 500 previously reported HBV strains 
had the rtI233V mutation. Two of these strains 
were from Southeast Asia and were genotype C,21 
and the third was a HBV strain found in gib-
bons.22 A lamivudine-resistant genotype C strain 
found in Chinese patients had a threonine at that 
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Figure 2. Sequence of Amino Acids 171 to 240 in the Reverse-Transcriptase Domain of HBV Polymerase in Three Patients.
The sequence of amino acids is shown before and after adefovir therapy and compared with three adefovir-resistant HBV isolates selected 
during adefovir treatment.13,14 The mutations that are associated with lamivudine or adefovir resistance are in red bold type. The wild-
type refers to a central European isolate of genotype D (European Molecular Biology Laboratory accession no. Y07587). The HBV DNA 
was extracted from serum and amplified in the reverse-transcriptase domain with the use of sense primer 374-390 TGGATGTGTCTGCGGC 
and antisense primer 995-973 CKTTGACADACTTTCCAATCAATAG. The gel-purified PCR products were sequenced in both directions by 
MWG Biotech. Alternatively, sequencing was also performed as described by Schildgen et al.7
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position, but this variant may not have been vi-
able because it had a truncated S gene.23 Thus, 
there is very little variation at rt233 and no obvi-
ous genotypic association. There is, however, at 
least one other example of primary adefovir re-
sistance. Two of three cases of in vivo adefovir 
resistance that we discussed in a previous report7 
involved HBV strains that had an rtL217R muta-
tion before adefovir therapy. This mutation is pres-
ent in most HBV strains with genotype A2, which 
are prevalent in Europe and the United States, but 
not in strains with other genotypes, including A1, 
which are found in Africa and Asia.20,24
Our observations demonstrate that some nat-
urally occurring HBV strains are primarily resis-
tant to adefovir. The rapid and strong effect of 
tenofovir in all three patients along with the in 
vitro data suggest that the patients’ nonadher-
ence to the medication was not the reason for 
the failure of adefovir therapy. Reactivation of 
HBV replication, as occurred in Patient 1, has also 
been reported in three patients by Van Bömmel 
and Berg,25 but sequencing data for HBV DNA 
have not been reported by these authors, and 
therefore it is not known whether these patients 
carried relevant HBV variants.
In agreement with a previous report,26 we found 
that the in vitro efficacy of tenofovir against 
wild-type HBV was similar to that of adefovir. 
Van Bömmel et al. reported that tenofovir was 
generally superior to adefovir in vivo,6 a finding 
that was most likely not caused by the presence 
of reverse-transcriptase variants. They ascribed this 
general superiority of tenofovir in vivo to the fact 
that the dose of the drug can be increased by 
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Figure 3. Inhibition of Intracellular HBV DNA Synthesis 
in Vitro by Increasing Concentrations of Adefovir, 
 Tenofovir, and Lamivudine (Panel A) and the Effect of 
Adefovir on the Production of Secreted Virus Particles 
(Panel B). 
Panel A shows the evaluation of the production of the 
wild-type or variant (rtI233V) HBV within transfected 
cells. Southern blots of extracts obtained six days after 
transfection were quantitatively evaluated by phosphoim-
aging (Fujifilm BAS 2500). The number of pixels in the 
boxed area corresponding to the open circular and lin-
ear forms of HBV DNA was quantitatively evaluated for 
all lanes and corresponded to a value of 100 percent 
for the untreated control. Panel B shows the effect of 
increasing concentrations of adefovir on the produc-
tion of wild-type HBV DNA and the rtI233V mutant 
HBV DNA secret ed to the transfected cells. The DNA 
was extracted and then amplified by PCR assay with 
the use of the subgenomic primers F1 5′CTCCA GTTC A-
GGAACAGTAAACCC3′ and the corresponding reverse 
primer R1 5′TTGTGAGCTCAGAAAGGCCTTGTAAGTT-
GGCG3′. Serial dilutions of a cloned HBV genome 
served as a control (Standard) for calibration of the PCR 
assay. Amplified products were analyzed on an ethidium 
bromide–stained agarose gel and quantified with the 
use of the Fluor-S MultiImager (Biorad) and Quantity 
One software.
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a factor of 10, whereas the dose of adefovir is 
fixed.25 Since the dose of adefovir cannot be in-
creased, the presence of naturally occurring HBV 
variants, as described here and in our earlier re-
port,7 may decrease its efficacy.
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